II. AMENDMENTS TO THE SPECIFICATION

Please amend the title as follows

---Pharmaceutical Combinations Comprising a PDE5 Inhibitor and an Angiotensin II Receptor Antagonist for the Treatment of Hypertension---

Please replace the paragraph beginning at page 6, line 1, with the following rewritten paragraphs:

The pyrazolo[4,3-*d*]pyrimidin-7-ones disclosed in EP A 0463756, EP A 0526004 and published international patent applications WO 93/06104, WO 98/49166, WO 99/54333, WO 00/24745, WO 00/27848, WO 01/27112, WO 01/98304 and WO 01/27113 ~~U.S. Patent Nos. 5,250,534, 5,346,901, 5,719,283, 5,272,147, 5,426,107, 6,743,719, 6,251,904, 6,458,951, 6,333,330, 6,670,366, 5,728,862, 5,998,436, 6,004,938, 6,133,284, 6,156,903, 6,232,306, 6,472,525, 6,573,279, 6,576,761, 6,583,147, 6,756,373, 6,809,200, 6,844,436, 6,430,557 and 6,677,335, and U.S. Patent Application Publication Nos. 2004/180994, 2001/039271, 2002/038024, 2003/176696, 2002/040140 and 2004/152712;~~ the pyrazolo[4,3-*d*]pyrimidin-4-ones disclosed in EP A 0995750, EP A 0995751 and published international patent application WO 93/07149 ~~U.S. Patent Nos. 6,333,330, 6,670,366, and 6,407,114~~; the pyrazolo[4,3-*d*]pyrimidines disclosed in published international patent applications WO 01/18004, WO 02/00660 and WO 02/59126 ~~U.S. Patent Nos. 6,777,419, and U.S. Patent Application Publication Nos. 2004/029900 and 2004/053945~~; the quinazolin-4-ones disclosed in published international patent application WO 93/12095 ~~U.S. Patent No. 5,482,941~~; the pyrido[3,2-d]pyrimidin-4-ones disclosed in published international patent application AWO 94/95663 U.S. Patent No. 5,591,742; the purin-4-ones disclosed in EP A 1002718 and in published international patent applications WO 94/00453 U.S. Patent Nos. 5,734,653, 6,442,982, 6,595,439 and 6,593,332 and U.S. Patent Application Publication Nos. 2003/004173 and 2003/013727; the hexahydropyrazino[2',1':6,1]pyrido[3,4-b]indolo-1,4-diones disclosed in published international application WO 95/19978 ~~U.S. Patent Nos. 6,025,494, 6,127,542, 6,143,329, 6,143,746, 6,369,059, 6,608,065 and 6,784,179 and U.S. Patent Application No. 2002/119976~~; the imidazo(5,1-*f*)[1,2,4]triazin-ones disclosed in EP A 1092719 and in published international application WO 99/24433 ~~U.S. Patent Nos. 6,503,908, 6,362,178, 6,566,360 and 6,890,922~~; the bicyclic compounds disclosed in published international application WO 93/07124 ~~U.S. Patent Nos. 5,576,322, 5,693,652 and 5,801,180~~ and the imidazoquinazolinones disclosed in Rotella DP et al; J. Med. Chem. 43(7), 1257-1263, 2000. ~~having any of the following chemical structures~~







and



Additional examples of PDE5 inhibitors for use with the invention include compounds that are within the scope of any of the following two general formulas:



herein R1 is methyl or ethyl; R2 is ethyl or n-propyl; and R3 and R4 are each independently H, or C1-C6 alkyl optionally substituted with C5-C7 cycloalkyl or with morpholino and pharmaceutically acceptable salts thereof, and



herein R1 is C1-C6 alkyl; R2 is H, methyl or ethyl; R3 is C2-C4 alkyl; R4 is C1-C4 alkyl optionally substituted with NR5R6, CN, CONR5R6 or CO_2R7; C2-C4 alkanoyl optionally substituted with NR5R6, CN, CONR5R6 or CO_2R7; or halo; R5 and R6 are each

~~independently H or C1-C4 alkyl, or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, 4-(NR8)-1-piperazinyl or 1-imidazolyl group wherein said group is optionally substituted by one or two C1-C4 alkyl groups; R7 is H or C1-C4 alkyl; and R8 is H, C1-C3 alkyl or hydroxy C2-C3 alkyl; and pharmaceutically acceptable salts thereof.~~

Please replace the paragraph beginning on page 6, line 19, with the following re-written paragraph:

The contents of the published patent applications and journal articles ~~above-cited patents or patent application publications~~ and in particular the general formulae of the therapeutically active compounds of the claims and exemplified compounds therein are incorporated herein in their entirety by reference thereto.